# Eli Lilly and Company: Phase 3 study closed enrollment, 15374 enrolled (Obesity, Overweight)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Eli Lilly and Company |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity |
| NCT ID | NCT05556512 |
| Phase | Phase 3 |
| Status | active not recruiting |
| Conditions | Obesity; Overweight |
| Intervention types | drug |
| Target enrollment | 15374 |
| Site countries | United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, France, Germany, Greece |
| Posted | 2022-09-27 |
| Planned start | 2022-10-11 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-07 |
| Last update posted | 2026-10-07 |

## Why this score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 3: multi-site, larger budget.
- 15374 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05556512). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.